# A Study of Silmitasertib (CX-4945) in Healthy Subject

> **NCT05817708** · PHASE1 · COMPLETED · sponsor: **Senhwa Biosciences, Inc.** · enrollment: 30 (actual)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** CX-4945

## Key facts

- **NCT ID:** NCT05817708
- **Lead sponsor:** Senhwa Biosciences, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-11-28
- **Primary completion:** 2023-03-23
- **Final completion:** 2023-06-20
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2025-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05817708

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05817708, "A Study of Silmitasertib (CX-4945) in Healthy Subject". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT05817708. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*